Quartz Bio

Last week, Quartz Bio said that it had been selected to provide bioinformatics support for biomarker projects conducted by the Debiopharm group, a Swiss-based biopharmaceutical company.

NEW YORK (GenomeWeb News) – The Debiopharm Group said on Thursday it has inked a one-year collaboration deal with Quartz Bio for support of the biopharmaceutical group’s translational projects.

Quartz Bio and the Swiss Institute of Bioinformatics are working together to develop and validate MegaClust, SIB's platform for analyzing flow cytomery data, so that they can use it to provide analysis services to pharmaceutical companies.

NEW YORK (GenomeWeb News) – A group of Swiss partners today announced a collaboration to develop, use, and promote a flow cytometry data analysis platform.

Quartz Bio, a newly minted bioinformatics consultancy outfit, is hoping to make its bread and butter by offering exploratory biomarker analysis and data management services to clients in the pharmaceutical industry.

NEW YORK (GenomeWeb News) – Merck Serono, the biopharmaceutical division of Merck KGaA, today said that it has spun out a bioinformatics firm, Quartz Bio, from its Entrepreneur Partnership Program launched earlier this year.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.